|
|
News Breaks | | | | February 21, 2013 | | 08:08 EDT |  | VRX | Valeant acquires U.S. rights to Targretin from Eisai for $65M
Eisai and Valeant announced that Valeant has acquired U.S. rights for Targretin capsules and Targretin gel 1% from Eisai for $65M upfront, plus potential contingent payments based on certain milestones. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application for Targretin to Valeant, with Valeant assuming responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain its rights to Targretin outside of the United States and continue to meet the needs of its distribution partners outside of the United States. | |
|
News For VRX From The Last 14 Days Check below for free stories on VRX the last two weeks. |
|
|
| May 24, 2013 | | 16:21 EDT |  | VRX | On The Fly: Closing Wrap
 Subscribe for More Information | | | 13:18 EDT | | VRX | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:33 EDT |  | VRX | Valeant calls active, near deal to buy Bausch & Lomb
Subscribe for More Information | | | 12:30 EDT |  | VRX | Valeant near deal to acquire Bausch & Lomb for $9B, WSJ reports
Bausch & Lomb is close to a deal to sell itself to Valeant for $9B in a deal that could be done as early as next week, reports The Wall Street Journal, citing people familiar with the matter. Shares of Valeant are trading sharply higher following the report, up $8.43, or 11.29%, to $83.10.Reference Link | | | 12:08 EDT | | VRX | Valeant up 11% after Dow says near deal to buy Bausch & Lomb
Subscribe for More Information | | | 12:07 EDT | | VRX | Bausch & Lomb near deal to sell itself to Valeant for around $9B, Dow says
| | | May 17, 2013 | | 14:48 EDT | | VRX | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information | | | 13:56 EDT | | VRX | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. | | | May 15, 2013 | | 19:37 EDT | | VRX | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | May 14, 2013 | | 17:48 EDT | | VRX | Lone Pine gives quarterly update on stakes
NEW STAKES: Valeant Pharmaceuticals (VRX), Virgin Media (VMED), Thermo Fisher Scientific (TMO), CME Group (CME), and Liberty Media (LMCA). INCREASED STAKES: Mead Johnson Nutrition (MJN), News Corp (NWSA), Intuitive Surgical (ISRG), Monsanto (MON), and Qualcomm (QCOM). DECREASED STAKES: Cognizant Technology Solutions (CTSH), Equinix (EQIX), Ralph Lauren (RL), Disney (DIS), and Oceaneering International (OII). LIQUIDATED STAKES: Facebook (FB), Crown Castle (CCI), Accretive Health (AH), Informatica (INFA), and NetEase (NTES). | | | | 13:55 EDT | | VRX | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information | |
|
|
|
|
|
|
